LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

17.31 -4.05

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

17.06

Максимум

Ключови измерители
By Trading Economics
Приходи	25M -43M
Продажби	-3.6M 65M
EPS	-0.48
Марж на печалбата	-65.788
Служители	298
EBITDA	-16M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+110.85% upside

Дивиденти
By Dow Jones
Следващи печалби	3.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-182M 1.7B
Предишно отваряне	21.36
Предишно затваряне	17.31

Настроения в новините

By Acuity

21%

79%

40 / 344 Класиране в Healthcare

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.06.2026 г., 21:51 ч. UTC

Значими двигатели на пазара

Merlin Shares Rally After Defense Department's Design Review Wraps

4.06.2026 г., 23:46 ч. UTC

Пазарно говорене

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4.06.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4.06.2026 г., 23:42 ч. UTC

Придобивния, сливания и поглъщания

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4.06.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

Energy Resources of Australia to Enter Trading Halt

4.06.2026 г., 23:34 ч. UTC

Пазарно говорене

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

4.06.2026 г., 23:08 ч. UTC

Пазарно говорене

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4.06.2026 г., 22:41 ч. UTC

Пазарно говорене

Australia Shares Set to Rise at the Open -- Market Talk

4.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.06.2026 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4.06.2026 г., 20:16 ч. UTC

Пазарно говорене

Mexican Demand Indicators Show Signs of Life -- Market Talk

4.06.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4.06.2026 г., 19:46 ч. UTC

Пазарно говорене

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4.06.2026 г., 19:38 ч. UTC

Пазарно говорене

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4.06.2026 г., 19:30 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4.06.2026 г., 18:47 ч. UTC

Придобивния, сливания и поглъщания

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4.06.2026 г., 18:38 ч. UTC

Печалби

Money Quote: Tech Weakness in Context -- WSJ

4.06.2026 г., 18:24 ч. UTC

Печалби

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4.06.2026 г., 17:09 ч. UTC

Пазарно говорене

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4.06.2026 г., 16:58 ч. UTC

Печалби

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4.06.2026 г., 16:46 ч. UTC

Пазарно говорене

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4.06.2026 г., 16:38 ч. UTC

Печалби

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

4.06.2026 г., 16:13 ч. UTC

Пазарно говорене

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4.06.2026 г., 16:11 ч. UTC

Пазарно говорене

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4.06.2026 г., 15:56 ч. UTC

Пазарно говорене

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

110.85% нагоре

12-месечна прогноза

Среден 38.67 USD 110.85%

Висок 46 USD

Нисък 29 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

40 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.